MedTrace Logo

A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma

NCT00640016 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-01-31

Study results available
· View outcomes & findings →

Summary

To investigate the effects of CAT-354 on airway hyper-responsiveness (AHR) in uncontrolled asthma.

Conditions

Interventions

OTHER

Placebo

Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.

BIOLOGICAL

CAT-354 1 mg/kg

CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

BIOLOGICAL

CAT-354 5 mg/kg

CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

OTHER

CAT-354 10 mg/kg

CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Sponsors & Collaborators

  • Cambridge Antibody Technology

    collaborator OTHER

  • PRA Health Sciences

    collaborator INDUSTRY

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Thomas Mayer, M.D. · PRA Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Australia
  • Germany
  • Netherlands
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640016 on ClinicalTrials.gov